DAVID SOUTHWELL - Corporate Board Profile

PTC THERAPEUTICS, INC.

Filing Date	Source Excerpt
2018-04-30	David Southwell Audit Committee Compensation Committee 57 Mr. Southwell has served as a member of our Board since 2005... 2017 Director Compensation Table: David Southwell Fees earned or paid in cash $69,673, Option awards $87,800, Total $157,473.
2019-04-25	David Southwell Audit Committee Compensation Committee 58 Mr. Southwell has served as a member of our Board since 2005. 2018 DIRECTOR COMPENSATION The following table sets forth information regarding compensation awarded to, earned by or paid to our directors, other than Dr. Peltz, during 2018: Name Fees earned or paid in cash ($) Option awards ($)(1) All other compensation ($) Total ($) David Southwell 76,000 169,537 — 245,537
2020-04-27	David Southwell Audit Committee Compensation Committee 59 Mr. Southwell has served as a member of our Board since 2005. ... During 2019, our non-employee directors were compensated for their service as directors, including as members of the various committees of our Board, as follows: ... David Southwell $66,250 fees earned or paid in cash, $276,355 option awards, total $342,605.
2021-04-29	Mr. Southwell has served as a member of our Board since 2005. He is currently the Chief Executive Officer, and a member of the board of directors, of TScan Therapeutics, Inc., a privately-held biotechnology company at which he has held this position since October 2018. Previously Mr. Southwell served as President and Chief Executive Officer of Inotek Pharmaceuticals, Inc., a biotechnology company from 2014 until its merger with Rocket pharmaceuticals Inc. in 2018. From March 2010 to September 2012, Mr. Southwell served as the Executive Vice President and Chief Financial Officer, and from 2008 to 2010 served as a member of the board of directors, of Human Genome Sciences, Inc., a biopharmaceutical company. Prior to joining Human Genome Sciences, he served as Executive Vice President and Chief Financial Officer of Sepracor, Inc., a research-based pharmaceutical company, from June 1994 to March 2008, and as Sepracor's Senior Vice President and Chief Financial Officer, from 1994 to 1995. From August 1988 until 1994, Mr. Southwell was associated with Lehman Brothers Inc., a securities firm, in various positions within the investment banking division. In addition to TScan, Mr. Southwell currently serves on the board of Rocket Pharmaceuticals, a Nasdaq-listed biotechnology company. From 2018 to 2019, Mr. Southwell served on the board of directors of Spero Therapeutics, Inc., a Nasdaq-listed biotechnology company. During 2016, Mr. Southwell served as a director of inVentive Health, Inc., a contract research organization prior to its recapitalization in late 2016. From 2007 to 2016, Mr. Southwell served on the board of directors of THL Credit, Inc., a Nasdaq-listed business development company under the Investment Company Act of 1940. Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College. We believe that Mr. Southwell is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry.
2023-04-26	David P. Southwell has served as a member of our Board since 2005. From October 2018 to March 2023, he served as the Chief Executive Officer, and a member of the board of directors, of TScan Therapeutics, Inc., a Nasdaq-listed biotechnology company. ... We believe that Mr. Southwell is qualified to serve on our Board because of his extensive executive leadership experience and knowledge of our industry.